Prospective, Multicenter, Non-interventional Study to Characterize Profile of Patient With Psoriatic Arthritis Depending on Whether Their Disease is Managed by a Dermatologist or by a Rheumatologist, and Starting Ustekinumab
Phase of Trial: Phase IV
Latest Information Update: 11 Oct 2018
At a glance
- Drugs Ustekinumab (Primary)
- Indications Psoriatic arthritis
- Focus Therapeutic Use
- Acronyms PROUST
- Sponsors Janssen-Cilag
- 03 Oct 2018 Planned End Date changed from 31 May 2019 to 31 Dec 2019.
- 03 Oct 2018 Planned primary completion date changed from 31 Oct 2018 to 30 Apr 2019.
- 31 Aug 2018 Biomarkers information updated